Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The comp

TD Cowen analyst Ritu Baral maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price

Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience i

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst con

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Offic

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% a

Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clin

Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the comp

Wells Fargo analyst Benjamin Burnett initiates coverage on Helus Pharma (NASDAQ:HELP) with a Over

US stocks trade higher as Dow Jones gains over 350 points. Tech shares rise by 2% while consumer sta

US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participan

U.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, sto

JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7

I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-rewa

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a B

Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and low

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst con

- Recently closed $50 million underwritten offering reinforces strong institutional investor convict

Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonerg

Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial opera

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP)

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorde

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP)

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorde

NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP

Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YOR

Health officials explored restricting specific antidepressants among SSRI drugs-sources

NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline o

Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 20

NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP),

NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP

I am upgrading Cybin Inc. to Buy, driven by recent regulatory and clinical tailwinds that favor its

Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to h

TD Cowen analyst Ritu Baral initiates coverage on Helus Pharma (NASDAQ:HELP) with a Buy rating an

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pr

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a B

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a cli

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(1.00) per share which missed the analyst c

Helus PharmaTM ("Helus") (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical com